NCT00216112 2016-02-19
Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Hoosier Cancer Research Network
Phase 2 Completed
Clinical Trials
6 trialsNCT00039585 2015-04-30
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor
National Cancer Institute (NCI)
Phase 2 Completed
NCT00928642 2014-10-21
Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
Henry M. Jackson Foundation for the Advancement of Military Medicine
Phase 2 Completed
NCT00510653 2013-08-23
Gleevec Study for Patients With Ovarian Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00840450 2012-11-19
Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin
NYU Langone Health
Phase 2 Terminated
NCT00006357 2012-09-24
STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed